Who are Octapressin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Antocin Ii, Minirin, Argipressin, NPSP558.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/felypressin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Octapressin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Octapressin (FELYPRESSIN) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Pain.

phase 2 Vasopressin V1a receptor Pain Recombinant protein Live · refreshed every 30 min

Target snapshot

Octapressin (FELYPRESSIN). Octapressin works by binding to the vasopressin V1a receptor, which blocks pain signals to the brain.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Octapressin TARGET	FELYPRESSIN		phase 2		Vasopressin V1a receptor
Antocin Ii	ATOSIBAN	Ferring Pharmaceuticals A/S	marketed	atosiban	Vasopressin V1a receptor	2000-01-01
Minirin	Minirin	Hormozgan University of Medical Sciences	marketed		Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor
Argipressin	Argipressin	Kristina Svennerholm	marketed		Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor
NPSP558	NPSP558	Shire	phase 3	Vasopressin V1a receptor antagonist	Vasopressin V1a receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Octapressin — Competitive Intelligence Brief. https://druglandscape.com/ci/felypressin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing